1 minute reading time (146 words)

MISTIE Treatment Success at University of Kansas

Dr. Paul Camarata, a neurosurgeon and investigator for the MISTIE trial, was interviewed today about the successful treatment of a patient at the University of Kansas Medical CenterMIS stands for minimally-invasive surgery and is the technique used to place a catheter into the patient's intracerebral hematoma. (ICH, also called intracerebral hemorrhage, is a type of stroke caused by bleeding in the brain). A drug called tissue plasminogen activator (tPA) is then administered into this catheter for 1 to 3 days to breakup the blood clot (by enhancing a natural process called thrombolysis) so it can be drained out of the catheter.

During the interview, Dr. Camarata mentions the MISTIE Phase II trial that  recently completed enrollment (see Dr. Hanley's presentation on the full study results) and talks about the forthcoming MISTIE Phase III trial.


<script src="http://player.ooyala.com/player.js?deepLinkEmbedCode=VhMGlmMzp_-8HaqIQOfxkxwbYHC7ChY4&height=300&embedCode=VhMGlmMzp_-8HaqIQOfxkxwbYHC7ChY4&width=533"></script>

Original report by Meryl Lin McKean of Fox-4 TV Kansas City

Location (Map)

Bedside worksheets Updated - Redoux
International Stroke Conference 2012 - Daniel Hanl...

Related Posts

MISTIE-3 Site Locations